Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
15.04.2025 15:04:51

EQS-News: GeoVax to Present Clinical Data at Upcoming April Industry Events

EQS-News: GeoVax, Inc. / Key word(s): Financial
GeoVax to Present Clinical Data at Upcoming April Industry Events

15.04.2025 / 15:04 CET/CEST
The issuer is solely responsible for the content of this announcement.


Data to be Presented on the Company’s GEO-CM04S1 and Gedeptin Programs

ATLANTA, GA - April 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in two upcoming industry events during April. Event details are as follows:

World Vaccine Congress, April 22-24, 2025, Washington, DC
Date/Time: April 24, 2025 at 10:25 a.m. EDT (Room 207A)
Session Title: Phase 2b Study Results That Evaluated and Compared GeoVax’s Multi-Antigen, Vaccine Candidate (GEO-CM04S1) to an Approved Vaccine Against COVID-19
Speaker: Don J. Diamond, PhD, Director, Division of Vaccine Research & Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center

For more information on the conference, please visit 
https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm

American Association of Cancer Research, April 25-30, 2025, Chicago, IL
Date/Time: April 29, 2025 from 9:00 a.m. to 12:00 p.m. CDT
Session Title: Viral-Vectored, Gene-Directed Prodrug Therapy (Gedeptin) in Needle-Accessible Solid Tumors
Speaker: J. Marc Pipas, MD, Executive Medical Director, Oncology 

For more information on the conference, please visit
https://www.aacr.org/meeting/aacr-annual-meeting-2025/

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Company Contact:
info@geovax.com
678-384-7220

Investor Relations Contact:
geovax@precisionaq.com
212-698-8696

View the original release on www.newmediawire.com


News Source: GeoVax, Inc.


15.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: GeoVax, Inc.
United States
ISIN: US3736782000
EQS News ID: 2118468

 
End of News EQS News Service

2118468  15.04.2025 CET/CEST

Analysen zu Geovax Labs Inc

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Dividendenaktien – Wall Street Live mit Tim Schäfer

In der heutigen Ausgabe von Wall Street Live geht es um defensivere Aktien, welche nicht so stark von der Zollpolitik beeinflusst sind. Was sind spannende Aktien und worin ist Tim investiert?
Diese und weitere Fragen beantwortet Tim Schäfer in der heutigen Ausgabe von Wall Street Live.

In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
🛑 Wichtig: Das Thema Rüstung ist gesellschaftlich wie ethisch komplex – in diesem Video beleuchten wir vor allem die börsentechnische Entwicklung und die wirtschaftlichen Auswirkungen globaler Ereignisse.

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Dividendenaktien – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’250.00 19.13
Short 12’500.00 13.53
Short 12’950.00 8.91
SMI-Kurs: 11’660.96 17.04.2025 17:31:31
Long 11’200.00 19.86
Long 10’960.00 13.74
Long 10’180.00 8.40
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}